Related Experiment Video

Updated: Nov 30, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K

Recent progress of antiviral therapy for coronavirus disease 2019

Mengmeng Zhao1, Jishou Zhang1, Hanli Li2

  • 1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan, China; Hubei Key Laboratory of Cardiology, Wuhan, China.

European Journal of Pharmacology
|November 16, 2020
PubMed

Insights

The efficacy of antiviral drugs for COVID-19 remains controversial. High-quality clinical trials are needed to confirm the safety and effectiveness of these coronavirus disease 2019 treatments.

Area of Science:

  • Virology
  • Infectious Diseases
  • Pharmacology

Background:

  • The COVID-19 pandemic necessitated rapid development of antiviral treatments.
  • Numerous antiviral agents have been investigated for treating coronavirus disease 2019.
  • The clinical effectiveness of these antiviral therapies remains a subject of debate.

Purpose of the Study:

  • To review recent findings on antiviral therapies for COVID-19.
  • To analyze the reasons behind the controversy in antiviral drug research.
  • To assess the quality of existing studies on antiviral treatments for coronavirus disease 2019.

Main Methods:

  • Literature review of clinical studies on antiviral drugs for COVID-19.
  • Analysis of factors contributing to controversial results in antiviral research.
  • Evaluation of the methodological quality of published trials.

Main Results:

  • The efficacy of many antiviral drugs, including remdesivir and hydroxychloroquine, for COVID-19 is not definitively established.
  • Inconsistent study designs and methodologies contribute to conflicting findings.
  • A significant portion of current research lacks the rigor of high-quality randomized clinical trials.

Conclusions:

  • The effectiveness and safety of antiviral treatments for COVID-19 require further rigorous investigation.
  • High-quality randomized clinical trials are essential to resolve controversies and guide clinical practice.
  • Standardized research protocols are needed to ensure reliable evidence on antiviral therapies for coronavirus disease 2019.
Keywords:
Antiviral therapyCOVID-19SARS-CoV-2

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.6K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.2K

Related Concept Videos

Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
330
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.6K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
999
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
89
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
798
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
777